CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Dasatinib + Omeprazoledrug
Likely dose
Dasatinib + Omeprazole 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00655746
NCT00655746Phase 1Completed
CompareCT.gov

The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects

Bristol-Myers Squibb·interventional·Posted Apr 10, 2008·Updated Dec 15, 2009

In Brief

A Phase 1 clinical trial evaluating Dasatinib + Omeprazole for Healthy. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the effect of omeprazole on the pharmacokinetics of dasatinib in healthy subjects and to assess the safety and tolerability of a single dose of dasatinib before and after 5 days of dosing with omeprazole in healthy subjects

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2008
Enrollment StartApr 1, 2008
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 18.2 years ago

Interventions

Dasatinib + Omeprazoledrug

Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days